156 related articles for article (PubMed ID: 24322377)
1. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Sudo K; Ishihara T; Hirata N; Ozawa F; Ohshima T; Azemoto R; Shimura K; Nihei T; Nishino T; Nakagawa A; Nakamura K; Hara T; Tada M; Mikata R; Tawada K; Yokosuka O; Nakaji S; Yamaguchi T
Cancer Chemother Pharmacol; 2014 Feb; 73(2):389-96. PubMed ID: 24322377
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M
Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
5. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).
Yamada D; Kobayashi S; Takahashi H; Iwagami Y; Akita H; Asukai K; Shimizu J; Yamada T; Tanemura M; Yokoyama S; Tsujie M; Asaoka T; Takeda Y; Morimoto O; Tomokuni A; Doki Y; Eguchi H
Ann Surg Oncol; 2024 Jul; 31(7):4621-4633. PubMed ID: 38546797
[TBL] [Abstract][Full Text] [Related]
6. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
7. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T
Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka T; Komatsu Y; Mizuno N; Tsuji A; Ohkawa S; Tanaka M; Iguchi H; Ishiguro A; Kitano M; Satoh T; Yamaguchi T; Takeda K; Kida M; Eguchi K; Ito T; Munakata M; Itoi T; Furuse J; Hamada C; Sakata Y
Br J Cancer; 2017 Feb; 116(4):464-471. PubMed ID: 28081543
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Hamada C; Okusaka T; Ikari T; Isayama H; Furuse J; Ishii H; Nakai Y; Imai S; Okamura S
Br J Cancer; 2017 Jun; 116(12):1544-1550. PubMed ID: 28472821
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Cao C; Kuang M; Xu W; Zhang X; Chen J; Tang C
Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Imaoka H; Ikeda M; Maehara K; Umemoto K; Ozaka M; Kobayashi S; Terashima T; Inoue H; Sakaguchi C; Tsuji K; Shioji K; Okamura K; Kawamoto Y; Suzuki R; Shirakawa H; Nagano H; Ueno M; Morizane C; Furuse J
BMC Cancer; 2020 Oct; 20(1):946. PubMed ID: 33004032
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
[TBL] [Abstract][Full Text] [Related]
14. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Okusaka T; Miyakawa H; Fujii H; Nakamori S; Satoh T; Hamamoto Y; Ito T; Maguchi H; Matsumoto S; Ueno H; Ioka T; Boku N; Egawa S; Hatori T; Furuse J; Mizumoto K; Ohkawa S; Yamaguchi T; Yamao K; Funakoshi A; Chen JS; Cheng AL; Sato A; Ohashi Y; Tanaka M;
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1053-1059. PubMed ID: 28210843
[TBL] [Abstract][Full Text] [Related]
15. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
17. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
[TBL] [Abstract][Full Text] [Related]
18. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ohkawa S; Okusaka T; Isayama H; Fukutomi A; Yamaguchi K; Ikeda M; Funakoshi A; Nagase M; Hamamoto Y; Nakamori S; Tsuchiya Y; Baba H; Ishii H; Omuro Y; Sho M; Matsumoto S; Yamada N; Yanagimoto H; Unno M; Ichikawa Y; Takahashi S; Watanabe G; Wakabayashi G; Egawa N; Tsuda M; Hosotani R; Hamada C; Hyodo I
Br J Cancer; 2015 Apr; 112(9):1428-34. PubMed ID: 25880004
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Song H; Han B; Park CK; Kim JH; Jeon JY; Kim IG; Kim HJ; Jung JY; Kim JH; Kwon JH; Jang G; Kim HY; Kim HS; Choi DR; Zang DY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):845-52. PubMed ID: 23978987
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Lee GW; Kim HJ; Ju JH; Kim SH; Kim HG; Kim TH; Kim HJ; Jeong CY; Kang JH
Cancer Chemother Pharmacol; 2009 Sep; 64(4):707-13. PubMed ID: 19151975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
